About Tune - Tune Therapeutics
Based in Durham, NC. and Seattle, WA., Tune was founded and built around a veteran leadership team with deep expertise in gene and cell therapy, genome editing, and epigenetics. Learn more about our team of scientists and experts as well as opportunities at the company.
Mastering the Epigenome - Home - Tune Therapeutics
Tune Therapeutics was founded upon cutting-edge advances in the mechanics of gene regulation. Our ‘genetic tuning’ technology enables exquisite levels of control over gene activity – activating, silencing, and fine-tuning the output of specific genes to …
Tune Therapeutics – The Science
With its unique ability to fine-tune cell properties – combined with the power to direct entire cell states, fates, and phenotypes via multiplex editing – genetic tuning opens the door to the rapid development and application of effective, regenerative therapeutics.
Tune Therapeutics – Tune Therapeutics Launches with Pioneering ...
Durham, N.C. and Seattle, December 2, 2021 – – Tune Therapeutics, a biotechnology company pioneering the creation of epi-therapeutic medicines, launched today with its powerful and precise genetic tuning platform, TEMPO.
Tune Therapeutics – Tune Therapeutics Presents First Data …
DURHAM, NC and SEATTLE, WA (December 5, 2023) – Leading epigenome editing company Tune Therapeutics presented data in support of its chronic Hepatitis B Virus (HBV) program, demonstrating the ability to durably silence essential mechanisms of viral replication and persistence across a range of model systems.
Tune Therapeutics – Tune Therapeutics Moves into Clinical …
DURHAM, NC and SEATTLE, WA (November 14, 2024) – Leading epigenome editing company Tune Therapeutics announced today that it has received clinical trial application (CTA) approval from the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) to initiate a Phase 1b clinical trial for TUNE-401 – an investigational epigenetic ...
Tune Therapeutics – Contact Us
Looking for more information on careers or partnerships with Tune? Need to contact one of our experts or leadership team with a media inquiry or invitation? We would love to hear from you.
News & Insights - Tune Therapeutics
Jan 7, 2025 · Tune Therapeutics Launches with Pioneering Epigenomic Control Platform to Master Gene Networks, Treat Broad Range of Diseases
Applications - Tune Therapeutics
With its unique ability to fine-tune cell properties – combined with the power to direct entire cell states, fates, and phenotypes via multiplex editing – genetic tuning opens the door to the rapid development and application of effective, regenerative therapeutics.
Tune Therapeutics – AASLD 2024: Tune Therapeutics Shows Near …
DURHAM, NC and SEATTLE, WA (November 19, 2024) – Leading epigenome editing company Tune Therapeutics showcased new data yesterday at the American Association for the Study of Liver Diseases (AASLD) conference, in support of its drive to develop a lasting, functional cure for chronic Hepatitis B Virus (HBV).